• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

白癜风患者的临床特征与免疫炎症标志物的关系。

Clinical profile of vitiligo patients and relationship with immuno-inflammatory markers.

机构信息

Dermatology Service, Hospital Universitário Professor Edgard Santos, Salvador, BA, Brazil.

Dermatology Service, Hospital Universitário Professor Edgard Santos, Salvador, BA, Brazil.

出版信息

An Bras Dermatol. 2024 Mar-Apr;99(2):196-201. doi: 10.1016/j.abd.2023.03.007. Epub 2023 Nov 18.

DOI:10.1016/j.abd.2023.03.007
PMID:37985303
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10943265/
Abstract

BACKGROUND

Vitiligo is the most common pigmentary disorder and is considered a chronic, cumulative, multifactorial disease. The crucial role of cytotoxic CD8+ T lymphocytes and the IFNγ/CXCL10 axis has been demonstrated in its pathogenesis.

OBJECTIVE

To evaluate the clinical profile and immuno-inflammatory markers in patients with vitiligo in a reference medical center.

METHODS

Cross-sectional study in which all patients with vitiligo seen at the medical center the from 2019 to 2022 were evaluated, to outline the clinical profile. Moreover, cardiovascular risk biomarkers (neutrophil/lymphocyte ratio and C-reactive protein levels) were measured, as well as cytokines and chemokines (TNFα, IFNγ, IL10, IL15 and CXCL10) in the serum of a subgroup of 30 patients.

RESULTS

There was a predominance of females, with a mean age of 43 years. Most were phototypes IV or V (71.3%), without comorbidities (77.55%), and without a family history of vitiligo (70.41%). Higher levels of neutrophil/lymphocyte ratio, C-reactive protein, and inflammatory cytokines/chemokines were documented in vitiligo patients when compared to the control group (non-significant). As relevant data, the highest values of CXCL10 were detected in patients with vitiligo versus controls, as well as in patients with disease of shorter duration (p<0.05).

STUDY LIMITATIONS

The number of assessed patients was small due to recruitment difficulties caused by the COVID-19 pandemic.

CONCLUSION

The present data contribute to confirming the relevant role of the IFNγ/CXCL10 axis in the pathogenesis of vitiligo, highlighting CXCL10 as a possible activity marker.

摘要

背景

白癜风是最常见的色素障碍性疾病,被认为是一种慢性、累积性、多因素疾病。细胞毒性 CD8+T 淋巴细胞和 IFNγ/CXCL10 轴在其发病机制中的关键作用已得到证实。

目的

评估参考医疗中心白癜风患者的临床特征和免疫炎症标志物。

方法

对 2019 年至 2022 年在该医疗中心就诊的所有白癜风患者进行横断面研究,以概述其临床特征。此外,还测量了心血管风险生物标志物(中性粒细胞/淋巴细胞比值和 C 反应蛋白水平),并在 30 例患者亚组的血清中测量了细胞因子和趋化因子(TNFα、IFNγ、IL10、IL15 和 CXCL10)。

结果

女性居多,平均年龄 43 岁。大多数患者为 IV 或 V 型肤色(71.3%),无合并症(77.55%),无白癜风家族史(70.41%)。与对照组相比,白癜风患者的中性粒细胞/淋巴细胞比值、C 反应蛋白和炎症细胞因子/趋化因子水平更高(无显著性差异)。有趣的是,与对照组相比,以及与疾病持续时间较短的患者相比,白癜风患者的 CXCL10 值更高(p<0.05)。

研究局限性

由于 COVID-19 大流行导致招募困难,评估的患者数量较少。

结论

目前的数据有助于证实 IFNγ/CXCL10 轴在白癜风发病机制中的重要作用,突出 CXCL10 作为一种可能的活性标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c415/10943265/b13815924fec/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c415/10943265/b13815924fec/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c415/10943265/b13815924fec/gr1.jpg

相似文献

1
Clinical profile of vitiligo patients and relationship with immuno-inflammatory markers.白癜风患者的临床特征与免疫炎症标志物的关系。
An Bras Dermatol. 2024 Mar-Apr;99(2):196-201. doi: 10.1016/j.abd.2023.03.007. Epub 2023 Nov 18.
2
Differential expression of serum CXCL9 and CXCL10 levels in vitiligo patients and their correlation with disease severity and stability: A cross-sectional study.白癜风患者血清CXCL9和CXCL10水平的差异表达及其与疾病严重程度和稳定性的相关性:一项横断面研究。
Indian J Dermatol Venereol Leprol. 2025 Jan-Feb;91(1):9-15. doi: 10.25259/IJDVL_793_2023.
3
Increased expression of CXCR3 and its ligands in patients with vitiligo and CXCL10 as a potential clinical marker for vitiligo.在白癜风患者中,CXCR3 及其配体的表达增加,CXCL10 可作为白癜风的潜在临床标志物。
Br J Dermatol. 2016 Jun;174(6):1318-26. doi: 10.1111/bjd.14416. Epub 2016 May 4.
4
Systemic CXCL10 is a predictive biomarker of vitiligo lesional skin infiltration, PUVA, NB-UVB and corticosteroid treatment response and outcome.系统性CXCL10是白癜风皮损皮肤浸润、补骨脂素加紫外线A(PUVA)、窄谱中波紫外线(NB-UVB)及皮质类固醇治疗反应和疗效的预测生物标志物。
Arch Dermatol Res. 2022 Apr;314(3):275-284. doi: 10.1007/s00403-021-02228-9. Epub 2021 Apr 17.
5
Chemokines in Vitiligo Pathogenesis: CXCL10 and 12.白癜风发病机制中的趋化因子:CXCL10和CXCL12。
J Clin Aesthet Dermatol. 2021 Sep;14(9):27-32.
6
A similar local immune and oxidative stress phenotype in vitiligo and halo nevus.白癜风和晕痣中相似的局部免疫及氧化应激表型。
J Dermatol Sci. 2017 Jul;87(1):50-59. doi: 10.1016/j.jdermsci.2017.03.008. Epub 2017 Mar 19.
7
A meta-analysis of chemokines in vitiligo: Recruiting immune cells towards melanocytes.一项关于白癜风中趋化因子的荟萃分析:将免疫细胞招募到黑色素细胞中。
Front Immunol. 2023 Feb 24;14:1112811. doi: 10.3389/fimmu.2023.1112811. eCollection 2023.
8
Circulating CXCL10 is increased in non-segmental vitiligo, in presence or absence of autoimmune thyroiditis.循环 CXCL10 在非节段性白癜风中增加,无论是否存在自身免疫性甲状腺炎。
Autoimmun Rev. 2017 Sep;16(9):946-950. doi: 10.1016/j.autrev.2017.07.006. Epub 2017 Jul 8.
9
Role of chemokines and the corresponding receptors in vitiligo: A pilot study.趋化因子及其相应受体在白癜风中的作用:一项初步研究。
J Dermatol. 2018 Jan;45(1):31-38. doi: 10.1111/1346-8138.14004. Epub 2017 Nov 8.
10
LRP1/CD91 is highly expressed in monocytes from patients with vitiligo - even after repigmentation.LRP1/CD91 在白癜风患者的单核细胞中高度表达——即使在复色后也是如此。
Exp Dermatol. 2021 Mar;30(3):390-395. doi: 10.1111/exd.14249. Epub 2020 Dec 14.

引用本文的文献

1
Candidate approaches for predicting vitiligo recurrence: an effective model and biomarkers.预测白癜风复发的候选方法:一种有效模型和生物标志物
Front Immunol. 2025 Feb 6;16:1468665. doi: 10.3389/fimmu.2025.1468665. eCollection 2025.
2
Markers of Metabolic Abnormalities in Vitiligo Patients.白癜风患者代谢异常标志物。
Int J Mol Sci. 2024 Sep 23;25(18):10201. doi: 10.3390/ijms251810201.
3
An Evaluation of the Hematological Markers of Systemic Inflammation and Oxidative Stress in Vitiligo: A Case-Control Study.白癜风患者全身炎症和氧化应激血液学标志物的评估:一项病例对照研究。

本文引用的文献

1
Chemokines in Vitiligo Pathogenesis: CXCL10 and 12.白癜风发病机制中的趋化因子:CXCL10和CXCL12。
J Clin Aesthet Dermatol. 2021 Sep;14(9):27-32.
2
Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review.Janus 激酶抑制剂治疗白癜风:综述。
Front Immunol. 2021 Nov 18;12:790125. doi: 10.3389/fimmu.2021.790125. eCollection 2021.
3
Prevalence of Vitiligo Among Adults in the United States.美国成年人白癜风患病率。
Cureus. 2024 Mar 12;16(3):e56034. doi: 10.7759/cureus.56034. eCollection 2024 Mar.
JAMA Dermatol. 2022 Jan 1;158(1):43-50. doi: 10.1001/jamadermatol.2021.4724.
4
Updates and new medical treatments for vitiligo (Review).白癜风的最新进展及新的医学治疗方法(综述)
Exp Ther Med. 2021 Aug;22(2):797. doi: 10.3892/etm.2021.10229. Epub 2021 May 25.
5
Systemic CXCL10 is a predictive biomarker of vitiligo lesional skin infiltration, PUVA, NB-UVB and corticosteroid treatment response and outcome.系统性CXCL10是白癜风皮损皮肤浸润、补骨脂素加紫外线A(PUVA)、窄谱中波紫外线(NB-UVB)及皮质类固醇治疗反应和疗效的预测生物标志物。
Arch Dermatol Res. 2022 Apr;314(3):275-284. doi: 10.1007/s00403-021-02228-9. Epub 2021 Apr 17.
6
Vitiligo: A Review.白癜风:综述。
Dermatology. 2020;236(6):571-592. doi: 10.1159/000506103. Epub 2020 Mar 10.
7
Vitiligo: Mechanisms of Pathogenesis and Treatment.白癜风:发病机制与治疗。
Annu Rev Immunol. 2020 Apr 26;38:621-648. doi: 10.1146/annurev-immunol-100919-023531. Epub 2020 Feb 4.
8
The Use of Janus Kinase Inhibitors in Vitiligo: A Review of the Literature.Janus 激酶抑制剂在白癜风中的应用:文献综述。
J Cutan Med Surg. 2019 May/Jun;23(3):298-306. doi: 10.1177/1203475419833609. Epub 2019 Mar 22.
9
C-Reactive Protein in Atherothrombosis and Angiogenesis.C 反应蛋白在动脉粥样血栓形成和血管生成中的作用。
Front Immunol. 2018 Mar 2;9:430. doi: 10.3389/fimmu.2018.00430. eCollection 2018.
10
Neutrophil to lymphocyte ratio in patients with vitiligo.白癜风患者的中性粒细胞与淋巴细胞比值
Postepy Dermatol Alergol. 2017 Oct;34(5):468-470. doi: 10.5114/ada.2017.71114. Epub 2017 Oct 31.